Get the Stockscreener App
19.96
6.55%
-1.40
After Hours:
20.24
0.28
+1.40%
Arcus Biosciences Inc stock is traded at $19.96, with a volume of 1.86M.
It is down -6.55% in the last 24 hours and down -6.29% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$21.36
Open:
$21.58
24h Volume:
1.86M
Relative Volume:
1.17
Market Cap:
$2.47B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-6.4595
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-0.35%
1M Performance:
-6.29%
6M Performance:
+106.41%
1Y Performance:
+66.33%
1-Day Range:
$19.48
$21.58
1-Week Range:
$19.48
$21.58
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
19.96 | 2.64B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know - TipRanks
Arcus Biosciences stock hits 52-week high at $21.03 By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week high at $21.03 - Investing.com
Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen - MarketBeat
(RCUS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - sharewise.com
Aug Decliners: How correlated is Arcus Biosciences Inc to the S P500Portfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews
What is Arcus Biosciences Inc.’s valuation compared to sectorTrend Reversal & Capital Efficient Trade Techniques - mfd.ru
Arcus Biosciences Grants Stock Options to Employees - intellectia.ai
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Bear Alert: How does Arcus Biosciences Inc score in quality rankingsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Responsive Playbooks and the RCUS Inflection - Stock Traders Daily
Market Review: Can Arcus Biosciences Inc be recession proofWeekly Risk Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-01-23 23:49:02 - baoquankhu1.vn
Arcus Biosciences (RCUS): Investor Outlook Reveals 43% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
EPS Watch: How correlated is Arcus Biosciences Inc to the S P5002025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Will Arcus Biosciences Inc. stock recover faster than marketPortfolio Risk Assessment & Free Daily Top Stock Picks for All Investors - bollywoodhelpline.com
Arcus Biosciences, Inc. (NYSE:RCUS) Sees Significant Increase in Short Interest - MarketBeat
Arcus Biosciences (NYSE:RCUS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Reveals a 51.45% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Bank of America Securities Keeps Their Hold Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences appoints new Chief Medical Officer - MSN
Arcus Biosciences (NYSE:RCUS) Trading Down 5.8%Time to Sell? - MarketBeat
Is Arcus Biosciences (RCUS) Using Casdatifan to Quietly Redefine Its Core Oncology Strategy? - Sahm
Goldman Sachs Upgrades Arcus Biosciences (RCUS) to 'Buy', Raises Price Target | RCUS Stock News - GuruFocus
Goldman Sachs Upgrades Arcus Biosciences (RCUS) - Nasdaq
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage - TechStock²
Arcus Biosciences (NYSE:RCUS) Shares Gap UpHere's What Happened - MarketBeat
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating - Investing.com India
Risk Check: What is Arcus Biosciences Incs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Arcus downgraded at Morgan Stanley on balanced risk-reward setup - MSN
Arcus Biosciences (RCUS) Valuation Check After Recent Share Price Pullback And 1 Year Gain - Yahoo Finance
Los Angeles Daily NewsArcus Biosciences, Inc. Common Stock (NYSE:RCUS) Stock Quote - FinancialContent
Wall Street Zen Downgrades Arcus Biosciences (NYSE:RCUS) to Sell - MarketBeat
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - Улправда
Arcus Biosciences (RCUS) CEO Terry Rosen donates 35,000 shares in Form 4 - Stock Titan
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Arcus Biosciences Inc. stock continue upward momentumWatch List & AI Optimized Trade Strategies - ulpravda.ru
Is Arcus Biosciences Inc. stock a buy for dividend growthWeekly Market Outlook & Smart Allocation Stock Tips - Улправда
Growth Review: Is Arcus Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Moving Stock Trade Plans - Улправда
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Is Arcus Biosciences Inc. stock attractive after correctionMarket Sentiment Report & Precise Trade Entry Recommendations - ulpravda.ru
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):